# Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma

> **NCT01145170** · PHASE2 · COMPLETED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 40 (actual)

## Conditions studied

- Diffuse Intrinsic Brainstem Gliomas

## Interventions

- **RADIATION:** Radiotherapy
- **BIOLOGICAL:** Nimotuzumab

## Key facts

- **NCT ID:** NCT01145170
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145170, "Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01145170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*